GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aratana Therapeutics Inc (NAS:PETX) » Definitions » EPS without NRI

Aratana Therapeutics (Aratana Therapeutics) EPS without NRI : $-0.27 (TTM As of Mar. 2019)


View and export this data going back to 2013. Start your Free Trial

What is Aratana Therapeutics EPS without NRI?

Aratana Therapeutics's earnings per share without non-recurring items for the three months ended in Mar. 2019 was $-0.14. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2019 was $-0.27.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Aratana Therapeutics's EPS without NRI or its related term are showing as below:

PETX's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 4.7
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Aratana Therapeutics's EPS (Diluted) for the three months ended in Mar. 2019 was $-0.14. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2019 was $-0.27.

Aratana Therapeutics's EPS (Basic) for the three months ended in Mar. 2019 was $-0.14. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2019 was $-0.27.


Aratana Therapeutics EPS without NRI Historical Data

The historical data trend for Aratana Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aratana Therapeutics EPS without NRI Chart

Aratana Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
EPS without NRI
Get a 7-Day Free Trial -1.30 -2.45 -0.95 -1.17 -0.32

Aratana Therapeutics Quarterly Data
Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.19 -0.14 0.19 -0.18 -0.14

Competitive Comparison of Aratana Therapeutics's EPS without NRI

For the Biotechnology subindustry, Aratana Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aratana Therapeutics's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aratana Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Aratana Therapeutics's PE Ratio without NRI falls into.



Aratana Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aratana Therapeutics  (NAS:PETX) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Aratana Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Aratana Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Aratana Therapeutics (Aratana Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
11400 Tomahawk Creek Parkway, Suite 340, Leawood, KS, USA, 66211
Aratana Therapeutics Inc is a pet therapeutics company. Its main activity is the licensing, developing, and commercializing of innovative biopharmaceutical products for companion animals. The company's portfolio consists of therapeutic candidates such as small-molecule pharmaceuticals and large-molecule biologics. The main product candidates in development comprise small-molecule pharmaceuticals directed at treating osteoarthritis pain, inflammation, appetite stimulation, and post-operative pain. The firm's strategy consists of licensing proprietary technology from human biopharmaceutical companies or academia to develop therapeutics specifically for use in pets.
Executives
Roche Robert P Jr director 41 MOORES ROAD FRAZER PA 19355
Vort John Vander director C/O MPM ASSET MANAGEMENT, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Lowell W Robinson director 470 WEST END AVENUE, NEW YORK NY 10024
Wendy L Yarno director
David L Brinkley director 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Merilee Raines director IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Kevin Kotler 10 percent owner C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc 10 percent owner 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Healthcare Master Fund Ltd 10 percent owner C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Craig A. Barbarosh director 3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305
Hockaday Irvine O Jr director SPRINT NEXTEL CORPORATION, 2001 EDMUND HALLEY DRIVE, RESTON VA 20191
Craig A Tooman director, officer: President and CEO
Peter Steven St director, officer: PRESIDENT AND CEO MPM CAPITAL, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Laura Brege director C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Jay Lichter director C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211

Aratana Therapeutics (Aratana Therapeutics) Headlines

From GuruFocus

CureVac Welcomes Two Members to its Supervisory Board

By Marketwired Marketwired 06-24-2019